Literature DB >> 28095268

Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer: A Competing Risks Analysis.

Takashi Eguchi1, Sarina Bains1, Ming-Ching Lee1, Kay See Tan1, Boris Hristov1, Daniel H Buitrago1, Manjit S Bains1, Robert J Downey1, James Huang1, James M Isbell1, Bernard J Park1, Valerie W Rusch1, David R Jones1, Prasad S Adusumilli1.   

Abstract

Purpose To perform competing risks analysis and determine short- and long-term cancer- and noncancer-specific mortality and morbidity in patients who had undergone resection for stage I non-small-cell lung cancer (NSCLC). Patients and Methods Of 5,371 consecutive patients who had undergone curative-intent resection of primary lung cancer at our institution (2000 to 2011), 2,186 with pathologic stage I NSCLC were included in the analysis. All preoperative clinical variables known to affect outcomes were included in the analysis, specifically, Charlson comorbidity index, predicted postoperative (ppo) diffusing capacity of the lung for carbon monoxide, and ppo forced expiratory volume in 1 second. Cause-specific mortality analysis was performed with competing risks analysis. Results Of 2,186 patients, 1,532 (70.1%) were ≥ 65 years of age, including 638 (29.2%) ≥ 75 years of age. In patients < 65, 65 to 74, and ≥ 75 years of age, 5-year lung cancer-specific cumulative incidence of death (CID) was 7.5%, 10.7%, and 13.2%, respectively (overall, 10.4%); noncancer-specific CID was 1.8%, 4.9%, and 9.0%, respectively (overall, 5.3%). In patients ≥ 65 years of age, for up to 2.5 years after resection, noncancer-specific CID was higher than lung cancer-specific CID; the higher noncancer-specific, early-phase mortality was enhanced in patients ≥ 75 years of age than in those 65 to 74 years of age. Multivariable analysis showed that low ppo diffusing capacity of lung for carbon monoxide was an independent predictor of severe morbidity ( P < .001), 1-year mortality ( P < .001), and noncancer-specific mortality ( P < .001), whereas low ppo forced expiratory volume in 1 second was an independent predictor of lung cancer-specific mortality ( P = .002). Conclusion In patients who undergo curative-intent resection of stage I NSCLC, noncancer-specific mortality is a significant competing event, with an increasing impact as patient age increases.

Entities:  

Mesh:

Year:  2016        PMID: 28095268      PMCID: PMC5456376          DOI: 10.1200/JCO.2016.69.0834

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  40 in total

Review 1.  Sublobar resection: a movement from the Lung Cancer Study Group.

Authors:  Justin D Blasberg; Harvey I Pass; Jessica S Donington
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

2.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

3.  Prediction of major cardiovascular events after lung resection using a modified scoring system.

Authors:  Mark K Ferguson; Paramita Saha-Chaudhuri; John D Mitchell; Gonzalo Varela; Alex Brunelli
Journal:  Ann Thorac Surg       Date:  2014-02-22       Impact factor: 4.330

4.  A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis.

Authors:  L C Watters; T E King; M I Schwarz; J A Waldron; R E Stanford; R M Cherniack
Journal:  Am Rev Respir Dis       Date:  1986-01

5.  Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension.

Authors:  L H Steenhuis; H J Groen; G H Koëter; T W van der Mark
Journal:  Eur Respir J       Date:  2000-08       Impact factor: 16.671

6.  Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer.

Authors:  Mark F Berry; Chi-Fu Jeffrey Yang; Matthew G Hartwig; Betty C Tong; David H Harpole; Thomas A D'Amico; Mark W Onaitis
Journal:  Ann Thorac Surg       Date:  2015-05-16       Impact factor: 4.330

7.  Surgical management and outcomes of elderly patients with early stage non-small cell lung cancer: a nested case-control study.

Authors:  Caroline Rivera; Pierre-Emmanuel Falcoz; Alain Bernard; Pascal A Thomas; Marcel Dahan
Journal:  Chest       Date:  2011-03-24       Impact factor: 9.410

8.  Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit.

Authors:  Helen A Powell; Laila J Tata; David R Baldwin; Rosamund A Stanley; Aamir Khakwani; Richard B Hubbard
Journal:  Thorax       Date:  2013-05-17       Impact factor: 9.139

9.  Association of chronic obstructive pulmonary disease and tumor recurrence in patients with stage IA lung cancer after complete resection.

Authors:  Yasuo Sekine; Yoshito Yamada; Masako Chiyo; Takekazu Iwata; Takahiro Nakajima; Kazuhiro Yasufuku; Makoto Suzuki; Takehiko Fujisawa
Journal:  Ann Thorac Surg       Date:  2007-09       Impact factor: 4.330

10.  Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC.

Authors:  Yasuo Sekine; Mehrdad Behnia; Takehiko Fujisawa
Journal:  Lung Cancer       Date:  2002-07       Impact factor: 5.705

View more
  74 in total

1.  Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.

Authors:  Yang Qu; Katsura Emoto; Takashi Eguchi; Rania G Aly; Hua Zheng; Jamie E Chaft; Kay See Tan; David R Jones; Mark G Kris; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2018-11-29       Impact factor: 15.609

2.  Competing Risk Analysis in Lung Cancer Patients Over 80 Years Old Undergoing Surgery.

Authors:  Haruaki Hino; Takahiro Karasaki; Yukihiro Yoshida; Takeshi Fukami; Atsushi Sano; Makoto Tanaka; Yoshiaki Furuhata; Kosuke Kashiwabara; Junji Ichinose; Mitsuaki Kawashima; Jun Nakajima
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

3.  Analyzing competing risks in the treatment of lung cancer: a good start.

Authors:  Jae Y Kim
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

4.  Competing risks analysis in the prognostic assessment of patients undergoing lung resection.

Authors:  Takashi Eguchi; Prasad S Adusumilli
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

5.  A complicated clinical problem: surgical treatment decisions for patients with early-stage lung cancer.

Authors:  Jianfei Shen; Yang Liu; Chengyang Dai; Baofu Chen; Chang Chen; Gaetano Rocco; Alessandro Brunelli; Chia-Chuan Liu; Rene Horsleben Petersen; Jianxing He
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

6.  Moving beyond disease-focused decision making: understanding competing risks to personalize lung cancer treatment for older adults.

Authors:  Lauren J Taylor; James D Maloney
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

7.  Stereotactic body radiotherapy for operable, early stage non-small cell lung cancer-let's all take a deep breath.

Authors:  Eric B Howell; Kathleen S Berfield; Douglas E Wood
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

8.  Assessing the Generalizability of the National Lung Screening Trial: Comparison of Patients with Stage 1 Disease.

Authors:  Nichole T Tanner; Lin Dai; Brett C Bade; Mulugeta Gebregziabher; Gerard A Silvestri
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

9.  Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer.

Authors:  Jacob Y Shin; Ja Kyoung Yoon; Gaurav Marwaha
Journal:  Lung       Date:  2018-03-17       Impact factor: 2.584

10.  A Decision Analysis of Follow-up and Treatment Algorithms for Nonsolid Pulmonary Nodules.

Authors:  Mark M Hammer; Lauren L Palazzo; Andrew L Eckel; Eduardo M Barbosa; Chung Yin Kong
Journal:  Radiology       Date:  2018-11-20       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.